We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-11.26%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$800M
AUM Growth
-$414M
Cap. Flow
-$240M
Cap. Flow %
-29.97%
Top 10 Hldgs %
59.99%
Holding
111
New
25
Increased
21
Reduced
27
Closed
33

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$26.8M
2
MRK icon
Merck
MRK
+$25.8M
3
PFE icon
Pfizer
PFE
+$19.8M
4
ABBV icon
AbbVie
ABBV
+$14.1M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$13.5M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$21.3M
2
VRNT
Verint Systems
VRNT
+$16.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$12.8M
4
VTRS icon
Viatris
VTRS
+$11.3M
5
PTCT icon
PTC Therapeutics
PTCT
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 65.88%
2 Technology 4.53%
3 Consumer Discretionary 1.29%
4 Communication Services 0.33%
5 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIST icon
76
Milestone Pharmaceuticals
MIST
$138M
$125K 0.02%
+67,992
New +$1.18M
CLRB icon
77
Cellectar Biosciences
CLRB
$20.5M
$111K 0.01%
292
– –
ABEO icon
78
Abeona Therapeutics
ABEO
$366M
– –
-28,819
Closed -$2.36M
ASMB icon
79
Assembly Biosciences
ASMB
$498M
– –
-7,354
Closed -$1.81M
BLUE
80
DELISTED
bluebird bio
BLUE
– –
-4,979
Closed -$5.66M
BMRN icon
81
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-251,382
Closed -$21.3M
BURL icon
82
Burlington
BURL
$23.2B
– –
-19,500
Closed -$4.45M
CSTE icon
83
Caesarstone
CSTE
$72.3M
– –
-354,357
Closed -$5.34M
CYTK icon
84
Cytokinetics
CYTK
$10.5B
– –
-268,747
Closed -$2.85M
FISV
85
Fiserv Inc
FISV
$28.8B
– –
-67,279
Closed -$7.78M
GILD icon
86
CALL
Gilead Sciences
GILD
$162B
– –
-500,000
Closed -$32.5M
IBB icon
87
PUT
iShares Biotechnology ETF
IBB
$9.34B
– –
-1,000,000
Closed -$121M
IFRX icon
88
InflaRx
IFRX
$250M
– –
-330,000
Closed -$1.31M
KRNT icon
89
Kornit Digital
KRNT
$705M
– –
-101,759
Closed -$3.48M
KRYS icon
90
Krystal Biotech
KRYS
$10.1B
– –
-86,280
Closed -$4.78M
NVMI
91
Nova
NVMI
$12.4B
– –
-91,466
Closed -$3.46M
PTCT icon
92
PTC Therapeutics
PTCT
$5.68B
– –
-214,736
Closed -$10.3M
RARE icon
93
Ultragenyx Pharmaceutical
RARE
$2.45B
– –
-115,000
Closed -$4.91M
SEDG icon
94
SolarEdge
SEDG
$2.51B
– –
-56,822
Closed -$5.4M
SWTX
95
DELISTED
SpringWorks Therapeutics
SWTX
– –
-200,000
Closed -$7.7M
TEVA icon
96
CALL
Teva Pharmaceuticals
TEVA
$40.8B
– –
-1,220,600
Closed -$12M
TVTX icon
97
Travere Therapeutics
TVTX
$5.2B
– –
-317,381
Closed -$4.51M
VRNT
98
DELISTED
Verint Systems
VRNT
– –
-570,642
Closed -$16.1M
VTRS icon
99
Viatris
VTRS
$20.4B
– –
-560,000
Closed -$11.3M
WAB icon
100
Wabtec
WAB
$49.1B
– –
-40,000
Closed -$3.11M
1 2 3
4
5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2020 Portfolio in Review

As of Q1 2020, Sphera Funds Management held 111 positions worth $800M, down 34% from $1.21B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sphera Funds Management withdrew a net $240M in Q1 2020, closing 33 positions and reducing 27 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $21.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 52% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in AstraZeneca worth $25.5M.

  • Sphera Funds Management's largest Q1 2020 buy was AstraZeneca: 285,000 shares worth $25.5M.
  • Sphera Funds Management added most to Merck in Q1 2020, an estimated $25.8M increase.
  • Sphera Funds Management's biggest Q1 2020 reduction was Johnson & Johnson, cutting an estimated $12.8M.
  • Sphera Funds Management fully exited BioMarin Pharmaceuticals in Q1 2020, selling an estimated $21.3M.
  • Sphera Funds Management's ten largest holdings make up 60% of its $800M portfolio in Q1 2020.
  • Sphera Funds Management opened 25 new positions and closed 33 in Q1 2020.
  • Sphera Funds Management's portfolio value fell 34% quarter-over-quarter to $800M.

Based on Sphera Funds Management's 13F filing for Q1 2020, filed 14 May 2020.